Title |
Outcomes in a Cohort of Women Who Discontinued Maternal Triple-Antiretroviral Regimens Initially Used to Prevent Mother-to-Child Transmission during Pregnancy and Breastfeeding—Kenya, 2003–2009
|
---|---|
Published in |
PLOS ONE, April 2014
|
DOI | 10.1371/journal.pone.0093556 |
Pubmed ID | |
Authors |
Timothy D. Minniear, Sonali Girde, Frank Angira, Lisa A. Mills, Clement Zeh, Philip J. Peters, Rose Masaba, Richard Lando, Timothy K. Thomas, Allan W. Taylor, for the Kisumu Breastfeeding Study Team |
Abstract |
In 2012, the World Health Organization (WHO) amended their 2010 guidelines for women receiving limited duration, triple-antiretroviral drug regimens during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV (tARV-PMTCT) (Option B) to include the option to continue lifelong combination antiretroviral therapy (cART) (Option B+). We evaluated clinical and CD4 outcomes in women who had received antiretrovirals for prevention of mother-to-child transmission and then discontinued antiretrovirals 6-months postpartum. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 14% |
Germany | 1 | 14% |
United States | 1 | 14% |
Unknown | 4 | 57% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 6 | 86% |
Practitioners (doctors, other healthcare professionals) | 1 | 14% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Ethiopia | 1 | <1% |
Switzerland | 1 | <1% |
Unknown | 111 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 24 | 21% |
Researcher | 16 | 14% |
Student > Bachelor | 14 | 12% |
Student > Postgraduate | 9 | 8% |
Student > Doctoral Student | 6 | 5% |
Other | 19 | 17% |
Unknown | 25 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 34 | 30% |
Nursing and Health Professions | 19 | 17% |
Social Sciences | 10 | 9% |
Psychology | 7 | 6% |
Agricultural and Biological Sciences | 5 | 4% |
Other | 10 | 9% |
Unknown | 28 | 25% |